Bacterial skin infections, especially by Staphylococcus aureus, can both initiate and propagate? many inflammatory skin diseases, particularly atopic dermatitis (AD). The mechanisms by which? this occurs are unclear, but many lines of evidence implicate the involvement of biologically active? staphylococcal bacterial products such as superantigen toxins, alpha toxin, and the cell-wall? lipoprotein lipoteichoic acid (LTA). The ability of these staphylococcal products to stimulate? cytokine production in keratinocytes could provide one mechanism by which staphylococcal skin? infections worsen AD. Both preliminary and published data from our group indicate that the lipid? mediator platelet-activating factor (PAF) can modulate the effects of these bacterial products on? keratinocyte cytokine production.
Three specific aims are planned to help define the mechanism(s)? by which bacterial products worsen skin disease which will allow novel treatment strategies for? patients with infected atopic dermatitis. The first objective will define the levels of these? staphylococcal products on clinically infected AD lesions, and generate biologically active wash fluid? from infected AD lesions for further studies for both this Project as well as for Project 2. The? second aim will use two novel model systems with PAF-R and toll-receptor-positive and -negative? epidermal cells to define the role of the PAF-R versus toll-like receptors in bacterial productmediated? cytokine production. The third objective will examine the ability of bacterial products to? induce cutaneous inflammation both in wild-type and a novel mouse model of atopic disease? (StatGVT mice). PAF-R-/- and MyD88-/- mice will be used to define the role of the PAF and toll-like? receptor system in these processes.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
United States
Zip Code
Chang, Daniel; Yao, Weiguo; Tiller, Christina J et al. (2015) Exhaled nitric oxide during infancy as a risk factor for asthma and airway hyperreactivity. Eur Respir J 45:98-106
Sarria, Edgar E; Mattiello, Rita; Yao, Weiguo et al. (2014) Atopy, cytokine production, and airway reactivity as predictors of pre-school asthma and airway responsiveness. Pediatr Pulmonol 49:132-9
Turner, Matthew J; Dasilva-Arnold, Sonia C; Yi, Qiaofang et al. (2013) Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice. Pediatr Dermatol 30:574-8
Walline, Crystal C; Sehra, Sarita; Fisher, Amanda J et al. (2013) Allergic airway disease in mice alters T and B cell responses during an acute respiratory poxvirus infection. PLoS One 8:e62222
Spandau, Dan F; Lewis, Davina A; Somani, Ally-Khan et al. (2012) Fractionated laser resurfacing corrects the inappropriate UVB response in geriatric skin. J Invest Dermatol 132:1591-6
Travers, Jeffrey B; Kozman, Amal; Yao, Yongxue et al. (2012) Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics. Pediatr Dermatol 29:289-96
Sawant, Deepali V; Sehra, Sarita; Nguyen, Evelyn T et al. (2012) Bcl6 controls the Th2 inflammatory activity of regulatory T cells by repressing Gata3 function. J Immunol 189:4759-69
DaSilva, Sonia C; Sahu, Ravi P; Konger, Raymond L et al. (2012) Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res 304:65-71
Byrne, A M; Goleva, E; Chouiali, F et al. (2012) Induction of GITRL expression in human keratinocytes by Th2 cytokines and TNF-?: implications for atopic dermatitis. Clin Exp Allergy 42:550-9
Stritesky, Gretta L; Muthukrishnan, Rajarajeswari; Sehra, Sarita et al. (2011) The transcription factor STAT3 is required for T helper 2 cell development. Immunity 34:39-49

Showing the most recent 10 out of 37 publications